Multiple SclerosisMUMSNCT07518381
Medication Understanding in MS
An observational study of Multiple Sclerosis, run by University of Nottingham.
Trial summary
The goal of this observational study is to learn how people with multiple sclerosis (MS) understand, organise, and use their medicines at home. The study aims to explore how people take their prescribed and non-prescribed medicines, what challenges they experience, and whether any safety issues arise in day-to-day… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 15 Apr 2026to 1 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: From outpatient neurology (Nottingham) and rehabilitation medicine (Derby) settings
Who may be able to join
- Adults aged 18 years and over with a confirmed diagnosis of multiple sclerosis
- Living in the community (not in residential care)
- Taking at least one prescribed medication
- Able to provide informed consent or, for those without capacity to provide informed consent, with a consultee available to provide consultee declaration and provide information during home-based medication review
- Willing and able to participate in a home-based medication review
Who cannot join
- Severe cognitive or communication impairment without a consultee to provide consultee declaration and medication-related information
- Participants for whom a home visit is deemed unsafe
- Non-English speakers
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Home-based Assessment of Medication Understanding and Use in People With Multiple Sclerosis
The goal of this observational study is to learn how people with multiple sclerosis (MS) understand, organise, and use their medicines at home. The study aims to explore how people take their prescribed and non-prescribed medicines, what challenges they experience, and whether any safety issues arise in day-to-day medication use.
Participants will take part in one home visit with trained student researchers. During the visit, researchers will review all medicines and supplements the participant uses, ask about routines and any difficulties, check medication packaging with permission, and ask a brief question about memory. No treatment changes will be made. Information will be reviewed by a senior clinician, and any safety concerns will be shared with the participant's usual healthcare team.
- Conditions
- Multiple Sclerosis
- Keywords
- polypharmacy, medication use, medication understanding, medication management, multiple sclerosis, adherence, medication burden, home medication review
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| People with multiple sclerosis | Adults with multiple sclerosis living in the community who will receive a single home-based medication review. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medication Burden (Descriptive)
Total number of prescribed and non-prescribed medications and supplements used by each participant, recorded during the home-based medication review. This includes dose, frequency, route, and source of each item. The outcome will be summarised descriptively (counts, means, ranges).
Measured: Baseline
Secondary outcomes (5)
Medication Adherence (MARS-5 Score)
Self-reported adherence measured using the 5-item Medication Adherence Report Scale (MARS-5). Scores range from 5 to 25, with higher scores indicating better adherence. Results will be summarised descriptively.
Measured: Baseline
Medication-Related Challenges
Proportion of participants reporting difficulties with medication supply, administration, formulation, or perceived effectiveness, based on structured trigger questions. Reported descriptively.
Measured: Baseline
Subjective Cognitive Decline (Single-Item Question)
("Yes"/"No") to the validated single-item subjective cognitive decline question ("Do you feel you have more problems with your memory than most?"). Used to contextualise medication-taking behaviours. Summarised descriptively.
Measured: Baseline
Medication Organisation and Use of Aids
Use of medication aids such as dosette boxes, blister packs, phone reminders, or charts. Recorded as present/absent and described using frequencies.
Measured: Baseline
Medication Storage and Safety Issues
Number and type of potential safety issues identified during the home visit, including expired medicines, duplicate supplies, unmonitored supplements, or storage concerns. Summarised descriptively.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2026
- Study start15 Apr 2026 (estimated)
- Primary completion15 Jul 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospitals of Derby and Burton NHS Foundation Trust, Nottingham University Hospitals NHS Trust
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07518381
- Sponsor's protocol ID
- 26008
- Other IDs
- 368655
- Acronym
- MUMS
- Status last verified
- Mar 2026
- First submitted
- 25 Mar 2026
- Last updated
- 8 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Home-based Assessment of Medication Understanding and Use in People With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07518381
- Acronym / sponsor ID
- MUMS / 26008
- Conditions
- Multiple Sclerosis
- Keywords
- polypharmacy, medication use, medication understanding, medication management, multiple sclerosis, adherence, medication burden, home medication review
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Collaborators
- University Hospitals of Derby and Burton NHS Foundation Trust, Nottingham University Hospitals NHS Trust
- Study start
- 15 Apr 2026 (estimated)
- Primary completion
- 15 Jul 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 8 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn how people with multiple sclerosis (MS) understand, organise, and use their medicines at home. The study aims to explore how people take their prescribed and non-prescribed medicines, what challenges they experience, and whether any safety issues arise in day-to-day medication use.
Participants will take part in one home visit with trained student researchers. During the visit, researchers will review all medicines and supplements the participant uses, ask about routines and any difficulties, check medication packaging with permission, and ask a brief question about memory. No treatment changes will be made. Information will be reviewed by a senior clinician, and any safety concerns will be shared with the participant's usual healthcare team.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| People with multiple sclerosis | – | –Adults with multiple sclerosis living in the community who will receive a single home-based medication review. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- From outpatient neurology (Nottingham) and rehabilitation medicine (Derby) settings
Key inclusion criteria (5 listed)
- Adults aged 18 years and over with a confirmed diagnosis of multiple sclerosis
- Living in the community (not in residential care)
- Taking at least one prescribed medication
- Able to provide informed consent or, for those without capacity to provide informed consent, with a consultee available to provide consultee declaration and provide information during home-based medication review
- Willing and able to participate in a home-based medication review
Key exclusion criteria (3 listed)
- Severe cognitive or communication impairment without a consultee to provide consultee declaration and medication-related information
- Participants for whom a home visit is deemed unsafe
- Non-English speakers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Medication Burden (Descriptive)
Time frame: Baseline
Total number of prescribed and non-prescribed medications and supplements used by each participant, recorded during the home-based medication review. This includes dose, frequency, route, and source of each item. The outcome will be summarised descriptively (counts, means, ranges).
5 secondary outcomes
Medication Adherence (MARS-5 Score)
Time frame: Baseline
Medication-Related Challenges
Time frame: Baseline
Subjective Cognitive Decline (Single-Item Question)
Time frame: Baseline
Medication Organisation and Use of Aids
Time frame: Baseline
Medication Storage and Safety Issues
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
Related trials for Multiple Sclerosis
Active, not recruitingPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
RecruitingObservational study
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Primary Progressive Multiple Sclerosis, Primary Progressive MS
RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by University of Nottingham.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laura Edwards, FRCP PhD (01332258238, laura.edwards@nottingham.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medication Burden (Descriptive) (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.